American Society of HematologyYour Approach to Treating this Transplant-Ineligible Patient with Ph+ ALL?

In ASH Clinical News, Dr. Geoffrey Uy, a professor in the Oncology Division at Washington University School of Medicine in St. Louis, discusses treatment options for a transplant-ineligible patient who has Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL). The patient under review is a 61-year-old female diagnosed with Ph+ ALL who has multiple comorbidities and […]

American Medical AssociationLooking for the Optimal Endocrine Partner for ER+, HR+, ERBB2- Advanced Breast Cancer

A phase 2 clinical trial involving 486 patients examined whether fulvestrant or letrozole is more effective in treating advanced breast cancer. The results, published in JAMA Oncology, confirmed that letrozole is the preferred treatment in patients with advanced forms of breast cancer. Although fulvestrant demonstrated significant antitumor activity, it did not significantly impact the overall […]

American Society of HematologyA Landscape of Germ Line Mutations in a Cohort of Inherited Bone Marrow Failure (IBMF) Patients

Bone marrow failure in children and young adults is often suspected to be inherited; however, in many cases, diagnosis remains uncertain. A new study involving 179 patients (from 173 families) found that implementing precision medicine at diagnosis can improve patient management, along with the use of family counseling. This study published in Blood expands the […]

Millennium Medical PublishingManagement of Well-Differentiated Neuroendocrine Tumors

Surgery still offers the best chance of cure for patients with neuroendocrine tumors (NETs). However, for locally advanced or metastatic well-differentiated tumors, medical therapy including theranostics, targeted therapies, and chemotherapy can all play a role. Clinical Advances in Hematology & Oncology reviews the diagnosis and management of these tumors.

Guideline CentralASCO Hepatocellular Carcinoma Guideline Updates

Available from Guideline Central, the free, quick-reference print and digital pocket guide covers the most recent American Society of Clinical Oncology (ASCO) Hepatocellular Carcinoma Guidelines. Accessed by web and offline mobile devices, the pocket guide covers key points, treatment, first- and second-line therapies, a downloadable PDF, and links to other resources in advanced hepatocellular carcinoma.

Haymarket MediaTreatment Approaches Differ by Age Group in Extremity Soft Tissue Sarcoma

Reference Source: JAMA Network OpenDesign: Retrospective study of 8,953 patients from the National Cancer Database; compared the use of definitive treatment between 2004 and 2014 of 1,280 young adults (YAs, aged 18-39 years); 3,937 patients aged 40-64 years; and 3,756 patients age 65+.Results: Amputation – 8.1% (YAs), 5.5% (40-64), 5.3% (65+). Chemotherapy – 39.4% (YAs), […]